Impact of the pharmaceutical smoking cessation service on the Spanish community pharmacy
CJ Gómez 1  
N Sánchez 2
A Mendoza 3
M Rubio 4
A Serrano 5
More details
Hide details
Community Pharmacis, Barcelona, Spain
Community Pharmacist, San Sebastián de los Reyes, Spain
Community Pharmacist, Reus, Spain
Research and Teaching Unit Parc Sanitari Sant Joan de Déu, Barcelona, Spain
Psychiatrist (Parc Sanitari Sant Joan de Déu, Barcelona, Spain
Community Pharmacist, Palma de Mallorca, Spain
CJ Gómez   

Community Pharmacist, Barcelona, Spain
Publish date: 2018-06-13
Tob. Prev. Cessation 2018;4(Supplement):A186
The smoking cessation services evaluated so far point out that pharmaceutical intervention in smoking cessation is cost-effective, that must be performed by health professionals and that it is more effective than medication together with advice. The community pharmacies are sanitary centres accessible to the entire population and this has to be taken advantage of to try to reduce the number of smokers in our population with the consequent improvement of patients’ health condition.

Objectives: To evaluate the impact of a smoking cessation service (CESAR) in the community pharmacy in comparison to the regular intervention in the rate of smoking cessation of smoking patients that go to the community pharmacies, as well as its cost-effectiveness and its cost-utility. To evaluate the improvement in the health-related quality of life of smoking patients.

Prospective, controlled non-randomized trial of 12 months of follow-up. 100 trained pharmacies will participate through the CESAR programme (intervention group) and 100 non-trained pharmacies (control group), that will recruit at least 5 patients per pharmacy. The trial has been classified as NO-EPA and approved by the Ethics Committee. The group assigned to the CESAR programme will carry out an initial visit, follow-up visits at days 7, 15, 30, 60, 90 and 180, and a final visit at month 12. The control group will conduct an initial visit, a follow-up visit at day 180 and a final visit at month 12. The endpoints of the trial will be: sociodemographic, motivation, dependence, cooximetry, quality of life, treatment adherence, direct and indirect cost of the health services used. The data will be recorded in the web platform: The data analysis will be performed with the statistical package STATA v12.

The effectiveness in the cessation will be evaluated, as well as the cost-effectiveness and cost-utility of the CESAR intervention, the first results being available in May 2018.

The study benefits from the collaboration of Pfizer without conflict of interest.